Enveda Raises $311M at $2B Valuation to Advance Nature-Based AI Drug Pipeline
AI-driven biotech company Enveda has raised $311 million in a new funding round, pushing its valuation to $2 billion. The company specializes in discovering drugs derived from natural compounds using artificial intelligence. Enveda is currently running clinical trials on treatments targeting skin conditions. It is also developing a drug aimed at sustaining weight loss in patients who discontinue GLP-1 medications. The fresh capital is expected to accelerate the progression of these nature-derived therapies through clinical development.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.



Discussion (0)
Log in to join the discussion and vote.
Log in